AtaiBeckley Inc. (ATAI)

NGM – Цена в реальном времени. Валюта: USD

5.29

+0.71 (15.50%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

5.33

+0.04 (0.76%)

После закрытия: Jun 26, 2026, 7:58 PM EDT

04.06.2026

AtaiBeckley nears key clinical catalysts, Jefferies stays positive with repeat ‘Buy' rating

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has kept Jefferies analysts bullish on the company following a fireside chat in New York City, with the firm reiterating a 'Buy' rating and a $10 price target on the company, implying roughly 120% upside from current levels. The firm's outlook centers on strengthening late-stage visibility across the company's psychedelic pipeline and what it described as an increasingly constructive regulatory backdrop.

28.05.2026

AtaiBeckley launches mental health patient impact grant program

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has announced the launch of a new Patient Impact Grant Program aimed at supporting non-profit organizations working to improve mental health outcomes through community initiatives, education and research. The clinical-stage biotechnology company said the program will award three grants of $20,000 each to mission-driven organizations focused on advancing mental health support and patient outcomes.

28.05.2026

AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations

Three $20,000 grants open to non-profit, mission-driven organizations working across community support, education and stigma reduction, and ecosystem innovation and independent research NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced the launch of its Patient Impact Grant Program, which will award three grants of $20,000 each to non-profit, mission-driven organizations improving mental health outcomes through community leadership, education, and innovative research. Grant Funding Areas Community Support: Organizations who support equitable access to existing and emerging mental health treatments.

27.05.2026

AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026

NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that members of the Company's management team will participate in multiple upcoming investor conferences in June 2026.

13.05.2026

AtaiBeckley clinical pipeline advances toward multiple late-stage data catalysts, Jefferies says

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) is moving toward a series of late-stage clinical inflection points in its psychedelic drug pipeline, with multiple Phase III and Phase II readouts expected over the next several years that could help define the outlook for its $1B+ portfolio, according to Jefferies analysts. Following the company's Q1 results and corporate update, the firm highlighted multiple programs targeting treatment-resistant depression (TRD) and related psychiatric conditions, including BPL-003, VLS-01, and EMP-01, as key drivers of upcoming clinical and data readouts.

12.05.2026

AtaiBeckley targets Q2 start for Phase 3 depression trial as pipeline advances

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) is preparing to launch its pivotal Phase 3 program for its lead treatment-resistant depression therapy in the second quarter of 2026, while projecting its cash reserves will support operations into 2029 as the company advances multiple mental health treatment candidates through clinical development. In a statement released alongside the company's first quarter earnings on Tuesday, AtaiBeckley said its Phase 3 ReConnection program for BPL-003, a mebufotenin benzoate nasal spray being developed for treatment-resistant depression (TRD), remains on track to begin in Q2 2026 following an End-of-Phase 2 meeting with the US Food and Drug Administration.

12.05.2026

AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update

Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression on track for Q2 2026 VLS-01 Phase 2 Elumina topline results anticipated in Q4 2026 Consistent, convergent improvements demonstrated in EMP-01 Phase 2a trial across independent clinician-rated and patient-reported outcomes in Social Anxiety Disorder Cash and cash equivalents expected to fund operations through anticipated BPL-003 Phase 3 topline readouts, with runway into 2029 NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today reported financial results for the first quarter ended March 31, 2026, and provided a business update across its clinical pipeline. First Quarter 2026 Highlights BPL-003 (TRD): Phase 3 pivotal ReConnection program on track to initiate in Q2 2026.

Видео

No Data

There is no data to display

Пресс-релизы

28.05.2026

AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations

12.05.2026

AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update

27.04.2026

AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research

NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced it has received the Silver Award in OVID Health's 2026 Patient Participant Index (PPI), in collaboration with the Psychedelic Participant Advocacy Network (PsyPAN), in recognition of their joint efforts to strengthen participant partnership in psychedelic clinical research. The recognition highlights AtaiBeckley's multiyear collaboration with PsyPAN to integrate the lived experiences of clinical trial participants into the responsible development of novel mental health therapies and amplify these learnings across the sector.

22.04.2026

AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder

NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced expanded Phase 2a results for EMP-01 (oral R-MDMA) in adults with Social Anxiety Disorder (SAD) (n=70), demonstrating clinically meaningful and consistent improvements across clinician-rated symptoms, patient-reported experience, and real-world behavioral outcomes. At Day 43, EMP‑01 achieved a 38% reduction vs 15% on placebo (Hedges' g=0.84) on the patient-reported Social Phobia Inventory (SPIN), a 32% reduction vs 14% on placebo on the Subtle Avoidance Frequency Examination (SAFE), and a previously reported −11.9-point LS mean difference (LSMD) on the Liebowitz Social Anxiety Scale (LSAS) versus placebo (g=0.45), with 49% responder rates on both Clinical Global Impression-Improvement (CGI-I) (previously reported) and Patient Global Impressions of Change (PGI-C). EMP-01 was well tolerated, with no severe or serious adverse events.

AtaiBeckley Inc. (ATAI)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

AtaiBeckley Inc. (ATAI)

AtaiBeckley nears key clinical catalysts, Jefferies stays positive with repeat ‘Buy' rating

AtaiBeckley launches mental health patient impact grant program

AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations

AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026

AtaiBeckley clinical pipeline advances toward multiple late-stage data catalysts, Jefferies says

AtaiBeckley targets Q2 start for Phase 3 depression trial as pipeline advances

AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update

Видео

No Data

Пресс-релизы

AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations

AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update

AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research

AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder

AtaiBeckley nears key clinical catalysts, Jefferies stays positive with repeat ‘Buy' rating

AtaiBeckley launches mental health patient impact grant program

AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations

AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026

AtaiBeckley clinical pipeline advances toward multiple late-stage data catalysts, Jefferies says

AtaiBeckley targets Q2 start for Phase 3 depression trial as pipeline advances

AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update

Видео

No Data

Пресс-релизы

AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations

AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update

AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research

AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder

Search stocks

AtaiBeckley Inc. (ATAI)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

AtaiBeckley Inc. (ATAI)

AtaiBeckley nears key clinical catalysts, Jefferies stays positive with repeat ‘Buy' rating

AtaiBeckley launches mental health patient impact grant program

AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations

AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026

AtaiBeckley clinical pipeline advances toward multiple late-stage data catalysts, Jefferies says

AtaiBeckley targets Q2 start for Phase 3 depression trial as pipeline advances

AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update

Видео

No Data

Пресс-релизы

AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations

AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update

AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research

AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder

AtaiBeckley nears key clinical catalysts, Jefferies stays positive with repeat ‘Buy' rating

AtaiBeckley launches mental health patient impact grant program

AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations

AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026

AtaiBeckley clinical pipeline advances toward multiple late-stage data catalysts, Jefferies says

AtaiBeckley targets Q2 start for Phase 3 depression trial as pipeline advances

AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update

Видео

No Data

Пресс-релизы

AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations

AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update

AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research

AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder